Gaboxadol ( DrugBank: Gaboxadol )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 201 | Angelman syndrome | 5 |
| 206 | Fragile X syndrome | 2 |
201. Angelman syndrome
Clinical trials : 25 / Drugs : 40 - (DrugBank : 11) / Drug target genes : 22 - Drug target pathways : 20
Showing 1 to 5 of 5 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2019-004478-24-DE (EUCTR) | 05/06/2020 | 26/02/2020 | An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals with Angelman Syndrome (ELARA) An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individ ... | An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals with Angelman Syndrome (ELARA) - ELARA An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individ ... | Angelman Syndrome MedDRA version: 20.0;Level: PT;Classification code 10049004;Term: Angelman's syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Angelman Syndrome MedDRA version: 20.0;Level: PT;Classification code 10049004;Term: Angelman's syndr ... | Product Name: Gaboxadol monohydrate 0.5 mg (intended commercial formulation) Product Code: OV101 INN or Proposed INN: Gaboxadol Other descriptive name: GABOXADOL MONOHYDRATE Product Name: Gaboxadol monohydrate 2 mg (intended commercial formulation) Product Code: OV101 INN or Proposed INN: Gaboxadol Other descriptive name: GABOXADOL MONOHYDRATE Product Name: Gaboxadol monohydrate 5 mg (intended commercial formulation) Product Code: OV101 INN or Proposed INN: Gaboxadol Other descriptive name: GABOXADOL MONOHYDRATE Product Name: Gaboxadolmonohydrate 0.5 mg (intended commercial formulation) Product Code: OV101 INN or ... | Ovid Therapeutics Inc. | NULL | Not Recruiting | Female: yes Male: yes | 170 | Phase 3 | United States;Australia;Israel;Netherlands;Germany | ||
| 2 | EUCTR2019-002907-17-NL (EUCTR) | 19/02/2020 | 10/12/2019 | Clinical Trial to Evaluate the Efficacy and Safety of of OV101 in Pediatric Individuals With Angelman Syndrome Clinical Trial to Evaluate the Efficacy and Safety of of OV101 in Pediatric Individuals With Angelma ... | A MulticeNter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of OV101 in PediaTric IndividUals With AngelmaN SyndromE (NEPTUNE) - NEPTUNE A MulticeNter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Evalua ... | Angelman Syndrome MedDRA version: 20.0;Level: PT;Classification code 10049004;Term: Angelman's syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Angelman Syndrome MedDRA version: 20.0;Level: PT;Classification code 10049004;Term: Angelman's syndr ... | Product Name: Gaboxadol monohydrate 0.5 mg capsule Product Code: OV101 INN or Proposed INN: Gaboxadol Other descriptive name: GABOXADOL MONOHYDRATE Product Name: Gaboxadol monohydrate 2 mg capsule Product Code: OV101 INN or Proposed INN: Gaboxadol Other descriptive name: GABOXADOL MONOHYDRATE Product Name: Gaboxadolmonohydrate 0.5 mg capsule Product Code: OV101 INN or Proposed INN: Gaboxadol Ot ... | Ovid Therapeutics Inc. | NULL | Not Recruiting | Female: yes Male: yes | 95 | Phase 3 | United States;Australia;Israel;Germany;Netherlands;Italy | ||
| 3 | NCT04106557 (ClinicalTrials.gov) | September 9, 2019 | 25/9/2019 | A Study of OV101 in Individuals With Angelman Syndrome (AS) | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of OV101 in Pediatric Individuals With Angelman Syndrome A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Evalua ... | Primary Disease or Condition Being Studied: Angelman Syndrome (AS) | Drug: Gaboxadol;Drug: Placebo | Ovid Therapeutics Inc. | NULL | Completed | 2 Years | 12 Years | All | 104 | Phase 3 | United States;Australia;Germany;Israel;Netherlands |
| 4 | NCT02996305 (ClinicalTrials.gov) | January 2016 | 2/12/2016 | A Study in Adults and Adolescents With Angelman Syndrome | A Phase 2 Adult and Adolescent Angelman Syndrome Clinical Trial: A Randomized, Double-Blind, Safety and Efficacy Study of Gaboxadol A Phase 2 Adult and Adolescent Angelman Syndrome Clinical Trial: A Randomized, Double-Blind, Safety ... | Angelman Syndrome | Drug: OV101 Regimen 1;Drug: OV101 regimen 2;Other: Placebo | Ovid Therapeutics Inc. | NULL | Completed | 13 Years | 49 Years | All | 88 | Phase 2 | United States;Israel |
| 5 | EUCTR2019-004478-24-NL (EUCTR) | 18/03/2020 | An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals with Angelman Syndrome (ELARA) An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individ ... | An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals with Angelman Syndrome (ELARA) - ELARA An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individ ... | Angelman Syndrome MedDRA version: 20.0;Level: PT;Classification code 10049004;Term: Angelman's syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Angelman Syndrome MedDRA version: 20.0;Level: PT;Classification code 10049004;Term: Angelman's syndr ... | Product Name: Gaboxadol monohydrate 0.5 mg Product Code: OV101 INN or Proposed INN: Gaboxadol Other descriptive name: GABOXADOL MONOHYDRATE Product Name: Gaboxadol monohydrate 2 mg Product Code: OV101 INN or Proposed INN: Gaboxadol Other descriptive name: GABOXADOL MONOHYDRATE Product Name: Gaboxadol monohydrate 5 mg Product Code: OV101 INN or Proposed INN: Gaboxadol Other descriptive name: GABOXADOL MONOHYDRATE Product Name: Gaboxadolmonohydrate 0.5 mg Product Code: OV101 INN or Proposed INN: Gaboxadol Other desc ... | Ovid Therapeutics Inc. | NULL | Not Recruiting | Female: yes Male: yes | 200 | Phase 3 | United States;Australia;Israel;Germany;Netherlands |
206. Fragile X syndrome
Clinical trials : 108 / Drugs : 91 - (DrugBank : 36) / Drug target genes : 52 - Drug target pathways : 77
Showing 1 to 2 of 2 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04823052 (ClinicalTrials.gov) | May 25, 2022 | 24/3/2021 | Investigation of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) in Male Fragile X Syndrome Patients Aged 13-40 Investigation of Sulindac (HLX-0201) and Gaboxadol(HLX-0206) in Male Fragile X Syndrome Patients Age ... | A Phase 2, Placebo-controlled, Adaptive Design Study to Explore the Safety and Efficacy of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) and Possible Other Treatments in Adolescent and Adult Males With Fragile X Syndrome (FXS) A Phase 2, Placebo-controlled, Adaptive Design Study to Explore the Safety and Efficacy of Sulindac ... | Fragile X Syndrome | Drug: Sulindac (HLX-0201), dose strength 1;Drug: Sulindac (HLX-0201), dose strength 2;Drug: Placebo;Drug: Gaboxadol (HLX-0206) Drug: Sulindac (HLX-0201), dose strength 1;Drug: Sulindac (HLX-0201), dose strength 2;Drug: Placebo; ... | Healx Limited | NULL | Withdrawn | 13 Years | 40 Years | Male | 0 | Phase 2 | United States;Australia |
| 2 | NCT03697161 (ClinicalTrials.gov) | September 17, 2018 | 1/10/2018 | A Study of OV101 in Individuals With Fragile X Syndrome | A Phase 2, Randomized, Double-Blind, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of OV101 in Fragile X Syndrome A Phase 2, Randomized, Double-Blind, Parallel-Group Study Evaluating the Safety, Tolerability, and E ... | Fragile X Syndrome (FXS) | Drug: OV101 (gaboxadol) | Ovid Therapeutics Inc. | NULL | Completed | 13 Years | 22 Years | Male | 23 | Phase 2 | United States |